No Detail Found!

Evaluation of metformin use in non-critically hospitalized patients at A Single Tertiary Hospital in Saudi Arabia: A cross-sectional study

Author(s)
Mohannad Alshibani Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University,Jeddah,Saudi Arabia
Samah Alshehri Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University,Jeddah,Saudi Arabia
Abstract
The aim of this study was to assess the safety of metformin use in non-critically hospitalized patients. A crosssectional study was performed at a single tertiary hospital in Saudi Arabia between January 2019 and June 2019. Patients aged >18 years with a confirmed diagnosis of type 2 diabetes who were taking metformin prior to admission were included. The primary outcome was the appropriateness of metformin use in non-critically hospitalized patients. A total of 251 patients were included in this study. Metformin was appropriate in 96 patients (38.2%). There were 14 (5.6%) incidences of absolute contra-indications and 141 (56.1%) incidences of precautions. Non-Saudi patients were about 1.856 times more likely to receive an inappropriate metformin dosage regimen compared to Saudi patients (AOR= 1.856; P= 0.022, 95% CI= 1.093, 3.151). Additionally, patients with chronic kidney disease (stage 3A) were approximately 2 times less likely to receive an inappropriate metformin dosage regimen than patients on stage 5 (AOR= 0.482; P= 0.035, 95% CI= 0.243, 0.835). This study highlighted a high rate of inappropriate metformin use in non-critically hospitalized patients. However, patients who were non-Saudi and at an advanced stage of chronic kidney disease were more likely to receive an inappropriate metformin dosage regimen.
Publication Details
Page(s) 1347-1353
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 4, Year: 2025

Request the full text from PASTIC

Keywords
Diabetes, evaluation, Saudi Arabia, metformin, Hospitalization, Diabetes, Diabetes
References
Diabetes Association American .2022 .Diabetes care in the hospital: Standards of medical care in diabetes-. Diabetes Care, 45 : S244-S253.
Al-Rubeaan K,Bana FA,Alruwaily FG,Sheshah E,Alnaqeb D,AlQahtani AM,Ewais D,Al Juhani N,Hassan A,Youssef AM .2020 .Physicians' choices in the first- and second-line management of type 2 diabetes in the Kingdom of Saudi Arabia. , 28(1) : 329-337.
Alauddin T,Petite SE .2020 .Evaluation of the safety and efficacy of metformin use in hospitalized, noncritically ill patients. J. Pharm. Technol., 36(3) : 102-109.
Alfayez OM,Alsallum AA,Aljabri AF,Almutairi FS,AlAzzeh O,Almalki OS,Almohammed OA .2022 .The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia. , 10 : 989078.
Elhussein A anderson A,Bancks MP,Coday M,Knowler WC,Peters A,Vaughan EM,Maruthur NM,Clark JM,Pilla S JM .2022 .Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study. Lancet Reg. Heal, 6 : 100111.
Fayfman M,Galindo RJ,Rubin DJ,Mize DL,Anzola I,Urrutia MA,Ramos C,Pasquel FJ,Sonya Haw J,Vellanki P,Wang H,Albury BS,Weaver R,Cardona S,Umpierrez GE .2019 .A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care, 42(3) : 450-456.
Drug Administration Food .2016 .FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. FDA., : .
Garg R,Schuman B,Hurwitz S,Metzger C,Bhandari S C,Gonzalez-Lopez C,Wojeck BS C .2023 .Role of metformin in the management of type 2 diabetes: Recent advances. Polish Arch. Intern. Med, 133(6) : 16511.
Ilias I,Rizzo M,Zabuliene L M .2022 .Metformin: Sex/gender differences in its uses and effects-narrative review. Medicina, 58(3) : 430.
Kim T,Campbell DB,Au F,Ronksley PE,Weaver RG,Campbell DJT .2024 .Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada. , 26(4) : 1234-1243.
Korytkowski MT,Muniyappa R,Antinori-Lent K,Donihi AC,Drincic AT,Hirsch IB,Luger A,McDonnell ME,Murad MH,Nielsen C,Pegg C,Rushakoff RJ,Santesso N,Umpierrez GE .2022 .Management of hyperglycemia in hospitalized adult patients in noncritical care settings: An Endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab., 107(8) : 2101-2128.
Li L,Guan Z,Li R,Zhao W,Hao G,Yan Y,Xu Y,Liao L,Wang H,Gao L,Wu K,Gao Y,Li Y,Sargun A .2020 .Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus. Medicine, 99(46) : e23212.
Miao E,Zhang K,Liu J,Lin J,Yoo D,George CJ,Mohajan HK CJ .2023 .Hyperglycaemia among diabetes patients: A preventive approach. Innov. Sci. Technol, 2(6) : 27-33.
Mohammed T,Bowe M,Plant A,Perez M,Alvarez CA,Mortensen EM .2023 .Metformin use is associated with lower mortality in veterans with diabetes hospitalized with pneumonia. Clin. Infect. Dis., 76(7) : 1237-1244.
Oktora MP,de Vries ST,Hak E,Denig P .2023 .Sex disparities in treatment patterns after metformin initiation among patients with type 2 diabetes mellitus. Pharmacoepidemiol. Drug Saf, 32(12) : 1395-1405.
Ong AN,Tan CC,Cañete MT,Lim BA,Robles J .2021 .Association between metformin use and mortality among patients with type 2 diabetes mellitus hospitalized for covid-19 infection. J. ASEAN Fed. Endocr. Soc., 36(2) : 133-141.
Orloff J,Min JY,Mushlin A,Flory J .2021 .Safety and effectiveness of metformin in patients with reduced renal function: A systematic review. Diabetes, Obes. Metab., 23(9) : 2035-2047.
Pasquel FJ,Fayfman M,Umpierrez GE .2019 .Debate on insulin vs non-insulin use in the hospital setting-is it time to revise the guidelines for the management of inpatient diabetes. Curr. Diab. Rep, 19 : 65.
Pasquel FJ,Lansang MC,Dhatariya K,Umpierrez GE K .2021 .Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol., 9(3) : 174-188.
Rosinha PMO,Inácio IMR,Teixeira SM,Amaral CS .2011 .Hyperglycemia in hospitalized patients of a tertiary care hospital: Prevalence and treatment in two cross-sectional evaluations (. Arch. Endocrinol. Metab., 66(2) : 214-221.
Seisa MO,Saadi S,Nayfeh T,Muthusamy K,Shah SH,Firwana M,Hasan B,Jawaid T,Abd-Rabu R,Korytkowski MT,Muniyappa R,Antinori-Lent K,Donihi AC,Drincic AT,Luger A,Torres Roldan VD,Urtecho M,Murad Z,MH Z .2022 .A systematic review supporting the endocrine society clinical practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures. J. Clin. Endocrinol. Metab., 107(8) : 2139-2147.
Soric MM,Moorman JM,Boyle JA,Dengler-Crish CM .2016 .Prevalence and predictors of metformin prescribing in adults with type 2 diabetes mellitus: A national cross-sectional study. Pharmacotherapy, 36(7) : 715-722.
Squibb BM .2018 .Glucophage ® XR Label. BristolMyers Squibb Co, : 3-32.
van Vugt HA,Heijmans MJWM,de Koning EJP,Rutten GEHM .2020 .Factors that influence the intended intensity of diabetes care in a person-centred setting. Diabet. Med, 37(7) : 1167-1175.
Vellanki P,Rasouli N,Baldwin D,Alexanian S,Anzola I,Urrutia M,Cardona S,Peng L,Pasquel FJ,Umpierrez GE,Bakhtiari H,Wang CL,Jones J,Modzelewski K,Ensminger E,Haw JS,Fayfman M,Ramos C,Gomez P C .2019 .Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial. Diabetes, Obes. Metab., 21(4) : 837-843.
Wang SH,Shao W,Jiang QH,Zheng XL,Shen QB,Lin XY,Zhang QQ,Zhang LL,Shi XL,Wang WG,Li XJ .2023 .Risk factors for glycemic control in hospitalized patients with type 2 diabetes receiving continuous subcutaneous insulin infusion therapy. Diabetes Ther, 14 : 167-178.
Wångdahl J,Lytsy P,Mårtensson L,Westerling R .2014 .Health literacy among refugees in Sweden - A cross-sectional study. BMC Public Health, 14 : 1030.
0

Citations

0

Downloads

74

Views